Close Menu

More articles about Business, Policy & Funding

Although SACGHS has yet to finalize its recommendations to exempt diagnostic developers from infringing on gene-association patents, last week's meeting ignited a debate on whether such a recommendation can be acted upon by the HHS Secretary, whether this would harm innovation, and whether the committee's conclusions about gene patents' deleterious impact on patient access was support by evidence.

The draft report advising infringement-free use of patented genes has been criticized as "flawed" and potentially doing more damage than good.

The companies plan to mutually develop and co-market their proteomics platforms.

DTC personal genomics firms, such as 23andMe, "don't have a laboratory, but they do [genomic] interpretation," Penny Thompson, deputy director of CMS' Center for Medicaid and State Operations, said during a meeting of the HHS Secretary's Advisory Committee on Genetics, Health, and Society in Washington, DC, last week. "That doesn't fall under CLIA."

The firm, which also announced the hire of a new executive vice president for worldwide commercial operations, expects its Q3 revenues to be in line with analysts' expectations.

While the majority of the new funding will support genome-wide association studies, also benefiting from the federal stimulus package are research projects focused on copy number-variation analysis, gene expression, and bioinformatics.

The license gives Orchid up to $1 million in fees, as well as royalties and preferred customer status.

Nanosphere received FDA clearance for its influenza and respiratory virus test to run on its new Verigene SP System.

The Belgian firm will use the funds to further develop its label-free screening technology and commercialize assays.

The 970 grants awarded to 'omics projects comprise 7.5 percent of the NIH stimulus grants awarded so far, but the total funding awarded to these projects makes up 14 percent of NIH ARRA grant funding to date.

The SACGHS task force has suggested that genetic testing patents are not necessary for innovation and may, in some cases, block patient access. However, the recommendations are not final and are being discussed at a meeting in Washington, DC, this week.

Kylin characterizes pRNA as a “gear in the DNA packaging machinery” that can be modified with therapeutic RNA such as siRNA.

IP Update: Oct 8, 2009

Premium

USPTO Publishes Two Patents, Eight Patent Applications Related to RNAi

Just because the sponsors performed genomic analyses on samples collected during previously completed trials doesn't mean "they went on a fishing expedition," said FDA's Lawrence Lesko, discussing the agency's re-labeling of Vectibix and Erbitux with gene-response data.

The NHGRI grant will fund software development for cancer mutation analysis.

The firm will use the $250,000 fast-track grant to develop its tumor testing system.

According to the grant abstracts, the project is "an unprecedented partnership" between two large-scale sequencing centers — at Baylor College of Medicine and at the Broad Institute — and a network of research labs focused on the genetics of autism, brought together by the Autism Genome Project and the Autism Consortium.

While the funding will directly benefit UMMS researcher Michael Czech, it is also expected to be a boon for RXi Pharmaceuticals, which Czech co-founded, since the company holds an exclusive license to the delivery technology for therapeutic RNAi applications.

While few details about the plaintiff in the case, PSN Illinois, were available, court filings indicate that the company has initiated numerous and varied patent-infringement suits in recent years.

Silence said that it "expects the proposed transaction to be treated as a reverse takeover … [and will be] subject to due diligence and would be conditional upon shareholder approval."

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.